Recently, the Class I innovative product Befotertinib Mesylate Capsules (Chinese trade name: 赛美纳) of Betta Pharmaceuticals Co., Ltd. is approved by China NMPA. It is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that had progressed after prior EGFR tyrosine kinase inhibitor therapy, and with epidermal growth factor receptor (EGFR) T790M-mutated.

　　Befotertinib Mesylate is the third-generation EGFR tyrosine kinase inhibitor, which can selectively inhibit EGFR sensitive mutation and EGFR T790M drug-resistant mutation kinase. The marketing of this drug provides a new treatment option for NSCLC patients.